Premaitha Health PLC (LON:NIPT)‘s stock had its “buy” rating reissued by Panmure Gordon in a research report issued on Tuesday, Marketbeat reports. They currently have a GBX 24 ($0.34) price objective on the stock. Panmure Gordon’s price objective would indicate a potential upside of 142.91% from the company’s previous close. Separately, FinnCap reaffirmed a “corporate” […]
